Molecular Matrix, Inc. was incorporated in August 2011 as a preclinical stage biotechnology company. After 7 years of research and development, we received FDA clearance for our first product, a non-mineralized bone graft substitute.
We believe that medicine is a continuous quest to ensure that people receive the life-saving or life-enhancing treatments they need to return to full life.
MMI is dedicated to developing an innovative next-generation tissue regeneration technology for musculoskeletal applications. Osteopoietic Systems™ is our solution to the need for value-driven and safe tissue regeneration products.